Abstract:To assess low-abundance protein biomarkers associated with tumor progression, we have developed artificial catalytic antibodies based on well-defined metal clusters modified with rationally designed peptides, termed clusterbodies. Such clusterbodies possess favorable integrated features of matched ultrasmall sizes, intrinsic fluorescence, and enzyme-like catalytic and selective recognition properties that are inaccessible to traditional antibodies. Consequently, a quantitative assay with high accuracy and high sensitivity is established by measuring the fluorescence and catalytic chemiluminescence of metal clusters preferentially recognizing the protein biomarker, which is confirmed by the molecular-weight marker references of immunoblotting. The results of quantitative immunoblotting are highly close to that derived from the enzyme-linked immunosorbent assay, implying the reliability of this protocol. Remarkably, the detection limit of the aimed protein achieved is as low as 1.0 pg, one magnitude lower than that of the conventional immunoassay. The significant variation of expression levels of the biomarker in tumor cells evidently indicates their distinguished invasion ability. This platform has potential application in analyzing low-abundance protein biomarkers in complex biological matrixes, which is essential to corroborate tumor malignancy in early stage. It inspires the construction of clusterbody-based precise bioprobes with customized structures and integrative functions for advanced quantitative biosensing.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.analchem.1c00779.Information on the reagent, synthesis and characterization of clusterbodies, experimental details, and schematic illustration of peptide and synthesis of clusterbodies; UV–vis spectra of peptide and clusterbodies; fluorescence intensity and chemiluminescence intensity of two clusters; immunoblotting and invasion ability of Hela and Caski cells; ELISA of Hela and Caski cells; specificity of clusterbodies on cells; schematic illustration of electrophoresis; electrophoretic transfer and selective recognition; specificity of clusterbodies by immunoassay; time-dependent fluorescence immunoassay; electrophoretic transfer efficiency of MMP14 standard protein or protein from crude lysates of Hela cells; clusterbody I-based immunoblot analysis of MMP14 in Caski cells lysate; electrophoretic transfer efficiency of MMP14 standard protein or protein from crude lysates of Caski cells; P2-Au clusterbody-based immunoblot analysis of MMP14 in Hela and Caski cells lysate; and photo image of the xenotransplanted mouse (PDF)This article has not yet been cited by other publications.

Clusterbody Enables Flow Sorting-Assisted Single-Cell Mass Spectrometry Analysis for Identifying Reversal Agent of Chemoresistance

A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

Reversal in Multidrug Resistance by Magnetic Nanoparticle of Fe3o4 Loaded with Adriamycin and Tetrandrine in K562/A02 Leukemic Cells

A multiparametric fluorescent visualization approach for detecting drug resistance in living cancer cells

An Integrated Microfluidics Platform with High-Throughput Single-Cell Cloning Array and Concentration Gradient Generator for Efficient Cancer Drug Effect Screening.

Microfluidic cell sorting by stiffness to examine heterogenic responses of cancer cells to chemotherapy

Catalytic Clusterbody for Enhanced Quantitative Protein Immunoblot

Multidimensional Quantitative Measurement of Cancer Chemoresistance Through Differential ZIF-8 Nanoparticle Cellular Retention.

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based “combo” nanoagent together with PD-L1 blockade in reversing multidrug resistance

On-Cell Catalytic Detection of Epithelial-to-Mesenchymal Transition by a Clusterzyme Bioprobe

Robust Dual Enzyme Cascade‐Catalytic Cholesterol Depletion for Reverse Tumor Multidrug Resistance

Single-cell Lipidomics with High Structural Specificity by Mass Spectrometry.

In Situ Drug-Receptor Binding Kinetics in Single Cells: a Quantitative Label-Free Study of Anti-Tumor Drug Resistance

Single-Cell Diagnosis of Cancer Drug Resistance through the Differential Endocytosis of Nanoparticles between Drug-Resistant and Drug-Sensitive Cancer Cells

Discovering metabolic vulnerability using spatially resolved metabolomics for antitumor small molecule-drug conjugates development as a precise cancer therapy strategy

An Electrochemical Method to Assay the Reversal Effect on Multi-Drug Resistance in Tumor Cells

Reverting Chemoresistance of Targeted Agents by a Ultrasoluble Dendritic Nanocapsule.

Reverse anti-breast cancer drug resistance effects by a novel two-step assembled nano-celastrol medicine

Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles

Copper-Based Metal–Organic Framework Overcomes Cancer Chemoresistance through Systemically Disrupting Dynamically Balanced Cellular Redox Homeostasis

Multi-shell structured fluorescent-magnetic nanoprobe for target cell imaging and on-chip sorting.